Do you routinely obtain next generation sequencing for patients with metastatic renal cell carcinoma and if so, what is your approach to incorporating these results into treatment decision making?  

Currently, I do not routinely send NGS for patients with metastatic clear cell RCC as we do not have level 1 evidence that these results should guide treatment decisions. We do not have "actionable mutations" that would change or guide our treatment of choice. IMDC still remains our best risk strati...